Akebia Therapeutics
AKBA
171 hedge funds and large institutions have $123M invested in Akebia Therapeutics in 2026 Q2 according to their latest regulatory filings, with 38 funds opening new positions, 67 increasing their positions, 34 reducing their positions, and 36 closing their positions.
97% more repeat investments, than reductions
Existing positions increased: 67 | Existing positions reduced: 34
24% more call options, than puts
Call options by funds: $747K | Put options by funds: $602K
2.28% more ownership
Funds ownership: 37.96% → 40.24% (+2.3%)
6% more first-time investments, than exits
New positions opened: 38 | Existing positions closed: 36
0% more funds holding
Funds holding: 171 → 171 (0)
13% less capital invested
Capital invested by funds: $141M → $123M (-$18.2M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AQR Capital Management
Greenwich,
Connecticut
|
+$8.76M |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$4.58M |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
+$3.13M |
| 4 |
BlackRock
New York
|
+$1.54M |
| 5 |
Two Sigma Investments
New York
|
+$1.36M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$7.41M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$2.74M |
| 3 |
Citigroup
New York
|
-$2.06M |
| 4 |
Jane Street
New York
|
-$1.73M |
| 5 |
HF
HRT Financial
New York
|
-$1.36M |
AKBA Hedge Fund Activity: Q2 2026 in Review
171 of the 8,318 institutional investors tracked by Wall St. Rank reported a position in Akebia Therapeutics (AKBA) for Q2 2026, worth a combined $123M — down 13% from $141M a quarter earlier.
Buyers outnumbered sellers: 38 funds opened new AKBA positions and 36 closed out — a net gain of 2 holders — while 67 added to existing stakes and 34 trimmed.
The largest buyer was AQR Capital Management, adding an estimated $8.76M. The largest seller was State Street, cutting an estimated $7.41M.
- 171 institutional investors held Akebia Therapeutics (AKBA) as of Q2 2026, unchanged from Q1 2026.
- Funds reported $123M of Akebia Therapeutics stock for Q2 2026, down 13% quarter-over-quarter.
- 38 funds opened new Akebia Therapeutics positions in Q2 2026 and 36 closed out, a net change of +2 holders.
- The largest Akebia Therapeutics buyer in Q2 2026 was AQR Capital Management, an estimated $8.76M added.
- The largest Akebia Therapeutics seller in Q2 2026 was State Street, an estimated $7.41M sold.
Based on aggregated 13F filings for Q2 2026.